193 related articles for article (PubMed ID: 29133712)
1. Meningiomas: Objective assessment of proliferative indices by immunohistochemistry and automated counting method.
Chavali P; Uppin MS; Uppin SG; Challa S
Neurol India; 2017; 65(6):1345-1349. PubMed ID: 29133712
[TBL] [Abstract][Full Text] [Related]
2. Sensitivity and usefulness of anti-phosphohistone-H3 antibody immunostaining for counting mitotic figures in meningioma cases.
Fukushima S; Terasaki M; Sakata K; Miyagi N; Kato S; Sugita Y; Shigemori M
Brain Tumor Pathol; 2009; 26(2):51-7. PubMed ID: 19856215
[TBL] [Abstract][Full Text] [Related]
3. Phosphohistone H3 (PHH3) as a surrogate of mitotic figure count for grading in meningiomas: a comparison of PHH3 (S10) versus PHH3 (S28) antibodies.
Puripat N; Loharamtaweethong K
Virchows Arch; 2019 Jan; 474(1):87-96. PubMed ID: 30267302
[TBL] [Abstract][Full Text] [Related]
4. The mitosis-specific antibody anti-phosphohistone-H3 (PHH3) facilitates rapid reliable grading of meningiomas according to WHO 2000 criteria.
Ribalta T; McCutcheon IE; Aldape KD; Bruner JM; Fuller GN
Am J Surg Pathol; 2004 Nov; 28(11):1532-6. PubMed ID: 15489659
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of the mitotic index using the mitosis marker anti-phosphohistone H3 in meningiomas.
Kim YJ; Ketter R; Steudel WI; Feiden W
Am J Clin Pathol; 2007 Jul; 128(1):118-25. PubMed ID: 17580279
[TBL] [Abstract][Full Text] [Related]
6. Phosphohistone-H3 Proliferation Index Is Superior to Mitotic Index and MIB-1 Expression as a Predictor of Recurrence in Human Meningiomas.
Winther TL; Arnli MB; Salvesen Ø; Torp SH
Am J Clin Pathol; 2016 Oct; 146(4):510-20. PubMed ID: 27686177
[TBL] [Abstract][Full Text] [Related]
7. Better see to better agree: phosphohistone H3 increases interobserver agreement in mitotic count for meningioma grading and imposes new specific thresholds.
Duregon E; Cassenti A; Pittaro A; Ventura L; Senetta R; Rudà R; Cassoni P
Neuro Oncol; 2015 May; 17(5):663-9. PubMed ID: 25646026
[TBL] [Abstract][Full Text] [Related]
8. Automated nuclear segmentation in the determination of the Ki-67 labeling index in meningiomas.
Kim YJ; Romeike BF; Uszkoreit J; Feiden W
Clin Neuropathol; 2006; 25(2):67-73. PubMed ID: 16550739
[TBL] [Abstract][Full Text] [Related]
9. Significance of Staining Intensity in Ki-67 Proliferation Index in Meningiomas, and a Critical Review of the Literature on Proliferation Index Assessment.
Brasher OC; Nix JS; Gokden M
Ann Clin Lab Sci; 2024 Mar; 54(2):170-178. PubMed ID: 38802155
[TBL] [Abstract][Full Text] [Related]
10. Detection of progesterone receptor and the correlation with Ki-67 labeling index in meningiomas.
Mukherjee S; Ghosh SN; Chatterjee U; Chatterjee S
Neurol India; 2011; 59(6):817-22. PubMed ID: 22234191
[TBL] [Abstract][Full Text] [Related]
11. Proliferative potential of recurrent intracranial meningiomas as evaluated by labelling indices of BUdR and Ki-67, and tumour doubling time.
Kakinuma K; Tanaka R; Onda K; Takahashi H
Acta Neurochir (Wien); 1998; 140(1):26-31; discussion 31-2. PubMed ID: 9522904
[TBL] [Abstract][Full Text] [Related]
12. The Utility of Phosphohistone H3 in Inter-Observer Variability of Mitotic Count in Meningioma, is There Any Benefit?
Saffar H; Okhovat H; Arbabsoleymani S; Tavangar SM; Khoshnevisan A; Hajinasrollah G; Hamidi Afra Z; Saffar H
Asian Pac J Cancer Prev; 2021 Jul; 22(7):2049-2052. PubMed ID: 34319026
[TBL] [Abstract][Full Text] [Related]
13. The Ki-67 proliferation antigen in meningiomas. Experience in 600 cases.
Roser F; Samii M; Ostertag H; Bellinzona M
Acta Neurochir (Wien); 2004 Jan; 146(1):37-44; discussion 44. PubMed ID: 14740263
[TBL] [Abstract][Full Text] [Related]
14. The correlation between phosphorylated Histone H3 (PHH3) and p-STAT3 in Meningiomas.
Ozek E; Akdag H; Tosuner Z; Abdallah A; Hatiboglu MA
Clin Neurol Neurosurg; 2019 Mar; 178():46-50. PubMed ID: 30710729
[TBL] [Abstract][Full Text] [Related]
15. PCNA, Ki-67 and hTERT in residual benign meningiomas.
Maes L; Kalala JP; Cornelissen M; De Ridder L
In Vivo; 2006; 20(2):271-5. PubMed ID: 16634530
[TBL] [Abstract][Full Text] [Related]
16. Mitotic Index is an Independent Predictor of Recurrence-Free Survival in Meningioma.
Olar A; Wani KM; Sulman EP; Mansouri A; Zadeh G; Wilson CD; DeMonte F; Fuller GN; Aldape KD
Brain Pathol; 2015 May; 25(3):266-75. PubMed ID: 25040885
[TBL] [Abstract][Full Text] [Related]
17. Characterization of morphologically benign biologically aggressive meningiomas.
Rao S; Sadiya N; Doraiswami S; Prathiba D
Neurol India; 2009; 57(6):744-8. PubMed ID: 20139503
[TBL] [Abstract][Full Text] [Related]
18. DNA topoisomerase II-alpha and cyclin A immunoexpression in meningiomas and its prognostic significance: an analysis of 263 cases.
Korshunov A; Shishkina L; Golanov A
Arch Pathol Lab Med; 2002 Sep; 126(9):1079-86. PubMed ID: 12204057
[TBL] [Abstract][Full Text] [Related]
19. Correlation of apparent diffusion coefficient with Ki-67 proliferation index in grading meningioma.
Tang Y; Dundamadappa SK; Thangasamy S; Flood T; Moser R; Smith T; Cauley K; Takhtani D
AJR Am J Roentgenol; 2014 Jun; 202(6):1303-8. PubMed ID: 24848829
[TBL] [Abstract][Full Text] [Related]
20. Improving precise counting of mitotic cells in mantle cell lymphoma using phosphohistone H3 (PHH3) antibody.
Medani H; Elshiekh M; Naresh KN
J Clin Pathol; 2021 Oct; 74(10):646-649. PubMed ID: 32873701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
